| Literature DB >> 34211724 |
Ricardo Alonso1, Liliana Patrucco2, Berenice Silva3, Cecilia Quarracino4, María Barbara Eizaguirre3, Carlos Vrech5, Pablo López6, Edgar Carnero Contentti6, Norma Deri7, Adriana Carrá8, Aníbal Chercorff8, Verónica Tkachuk9, María Eugenia Balbuena9, Juan Pablo Pettinicchi6, Darío Tavolini10, Andrés Barboza11, Juan I Rojas2, Edgardo Cristiano2, Luciana Lázaro1, Orlando Garcea3, Nora Fernández Liguori1,12.
Abstract
BACKGROUND: The purpose of this study was to assess family planning (FP) among women with multiple sclerosis (WwMS).Entities:
Keywords: Multiple sclerosis; family planning; pregnancy
Year: 2021 PMID: 34211724 PMCID: PMC8216353 DOI: 10.1177/20552173211025312
Source DB: PubMed Journal: Mult Scler J Exp Transl Clin ISSN: 2055-2173
General characteristics of the studied Argentinean cohort (n = 428).
| General characteristics | Values | |
|---|---|---|
| Age at survey (years) | 40.5 (SD 10.94) | |
| Years since MS diagnosis, n (%) | <3 years | 128 (29.9%) |
| 3–5 years | 83 (19.4%) | |
| 6–10 years | 97 (22.7%) | |
| 11–20 years | 83 (19.4%) | |
| >20 years | 37 (8.6%) | |
| PDDS at survey, n (%) | ≤3 | 347 (81%) |
| 4–6 | 61 (14.2%) | |
| >6 | 20 (4.8%) | |
| Motherhood after MS diagnosis, n (%) | None | 346 (80.9%) |
| Currently pregnant | 4 (0.9%) | |
| One pregnancy | 51 (11.9%) | |
| Two or more pregnancies | 27 (6.3%) | |
| Pregnancy before MS diagnosis | Yes | 180 (42.1%) |
SD: standard deviation; MS: multiple sclerosis; PDDS: Patient Determined Disease Steps scale.
Differences between women with MS who became pregnant or not after MS diagnosis.
| Analysis variables | Pregnancy after MS diagnosis | p-value | ||
|---|---|---|---|---|
| Yes (n = 82) | No (n = 346) | |||
| Motherhood before MS diagnosis, n (%) | 28 (34.1%) | 152 (43.9%) | 0.11 | |
| Maternity desire after MS diagnosis, n (%) | Unchanged | 65 (79.3%) | 173 (50%) |
|
| Uncertain | 5 (6.1%) | 70 (20.2%) | ||
| Changed | 12 (14.6%) | 103 (29.8%) | ||
| Frequency of neurologist addressing family planning, n (%) | Never | 22 (26.8%) | 161 (46.5%) |
|
| Occasionally | 15 (18.3%) | 56 (16.2%) | ||
| Only at the patient’s request | 39 (47.6%) | 108 (31.2%) | ||
| On every consultation | 6 (7.3%) | 21 (6.1%) | ||
| Neurologist explained about risks related to DMTs and pregnancy, n (%) | Yes | 54 (65.9%) | 146 (42.2%) |
|
| No | 28 (34.1%) | 200 (57.8%) | ||
| Most common information source on MS treatments and pregnancy, n (%)a | Uncertain, none or informal | 19 (23.2%) | 168 (48.6%) |
|
| Formal | 63 (76.8%) | 178 (51.4%) | ||
aInformal: relatives or friends, internet, other MS patients. Formal: physicians or patients’ organizations. DMTs: Drugs modified treatment.Bold numbers mark the degree of significance.
Factors associated with pregnancy planning.
| Planned pregnancy(n = 46) | Unplanned pregnancy(n = 36) | p-value | ||
|---|---|---|---|---|
| Age at last pregnancy years, Mean (SD) | 32.98 (4.62) | 34.30 (5.93) | 0.37 | |
| Motherhood before MS diagnosis, n (%) | 18 (34.6) | 10 (33.3) | 0.91 | |
| Year of the last pregnancy, median (IQR) | 2014.50 (7) | 2014 (8.5) | 0.70 | |
| Information from health workers regarding family planning in the last pregnancy | Yes | 39 (84.8) | 22 (61.1) |
|
| No | 7 (15.2) | 14 (38.9) | ||
| Treatment before the last pregnancya | Injectable drugs | 31 (67.4) | 12 (46.2) | 0.08 |
| Other treatmentb | 15 (32.6) | 14 (53.8) | ||
| Pregnancy planning strategy used n (%) | Stopped DMT and CM at the same timea | 13 (28.2) | – | NA |
| Stopped DMT and continued CM for a timec | 10 (21.8) | – | NA | |
| Stopped DMT after positive pregnancy testd | 23 (50) | – | NA | |
Note: Patients that became pregnant after being diagnosed with Multiple Sclerosis: Information related to the last pregnancy.
SD: standard deviation; Injectable drugs: Interferon or glatiramer acetate, DMT: Drug modified treatment. CM: contraception method.
a7 Injectable drugs, 3 natalizumab and 3 dimethyl fumarate.
bOther treatment: Fingolimod, dimethyl fumarate, cladribine; natalizumab, ocrelizumab.
c1 ocrelizumab, 2 fingolimod, 2 cladribine.
d19 Injectable drugs, 1 natalizumab, 2 dimethyl fumarate.Bold numbers mark the degree of significance.
Multivariate logistic regression analysis: Variables independently associated with unplanned pregnancy (n = 428).
| Univariate model OR (95 %CI) | p value | Multivariate modela OR (95 %CI) | p value | |
|---|---|---|---|---|
| Age at last pregnancy | 1.5 (0.9–1.1) | 0.26 | – | – |
| MS duration at last pregnancy | 0.62 (0.2–1.9) | 0.41 | – | – |
| Motherhood before MS diagnosis | 0.99 (0.3–2.9) | 0.98 | – | – |
| Information from health workers regarding family planning before the last pregnancy | ||||
| Yes | 0.28 (0.04–0.8) |
| 0.27 (0.08–0.92) |
|
| Non-injection drug treatment before pregnancy | 2.4 (0.8–6.4) |
| 2.88 (1.01–8.21) |
|
aVariables were included in multivariate regression if univariate analysis suggested an association (p < 0.20) with unplanned pregnancy.Bold numbers mark the degree of significance.
Plans for future childbearing in women with MS.
| Analyisis variables | Future childbearing desire | p-value | |||
|---|---|---|---|---|---|
| Total (n = 230) | Yes (n = 112) | No (n = 118) | |||
| Age (years) | 32.37 (SD 5.56) | 30.28 (SD 5.51) | 34.36 (SD 4.84) |
| |
| Years since MS diagnosis, n (%) | ≤5 years | 153 (43.6%) | 83 (74.1%) | 70 (59.3%) |
|
| >5 years | 77 (23%) | 29 (25.9%) | 48 (40.7%) | ||
| PDDS, n (%) | <3 | 197 (85.6%) | 102 (91.1%) | 95 (80.5%) |
|
| ≥3 | 33 (14.4%) | 10 (8.9%) | 23 (19.5%) | ||
| Current MS treatment, n (%) | None | 29 (12.6%) | 12 (10.7%) | 17 (14.4%) | NA |
| Injectable | 38 (16.5%) | 26 (23.2%) | 12 (10.2%) | ||
| Oral | 118 (51.4%) | 58 (51.8%) | 60 (50.8%) | ||
| MA & Cladribine | 39 (16.9%) | 16 (14.3%) | 23 (19.5%) | ||
| Others | 6 (2.6%) | 0 | 6 (5.1%) | ||
| Childbearing before MS diagnosis, n (%) | No | 169 (73.5%) | 98 (87.5%) | 71 (60.2%) |
|
| Yes | 61 (26.5%) | 14 (12.5%) | 47 (39.8%) | ||
| Pregnancy after MS diagnosis, n (%) | No | 194 (84.3%) | 97 (86.6%) | 97 (82.2%) | 0.37 |
| Yes | 36 (15.7%) | 15 (13.4%) | 21 (17.8%) | ||
| Neurologist addressing family planning, n (%) | No | 96 (41.7%) | 37 (33%) | 59 (50%) |
|
| Yes | 134 (58.3%) | 75 (67%) | 59 (50%) | ||
Note: This analysis was carried out in WwMS ≤ 40 years.
SD: standard deviation; MS: multiple sclerosis; EDSS: Expanded disability status scale; MA: monoclonal antibodies; Others: azathioprine and rituximab; Injectable: glatiramer acetate, interferon. Oral drugs: fingolimod, dimethyl fumarate and teriflunomide; Monoclonal antibodies: ocrelizumab, alemtuzumab and natalizumab; PDDS: Patient Determined Disease Steps scale. NA: not applicable.Bold numbers mark the degree of significance.